Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Impel NeuroPharma stock | $9.94

Learn how to easily invest in Impel NeuroPharma stock.

Impel NeuroPharma Inc is a biotechnology business based in the US. Impel NeuroPharma shares (IMPL) are listed on the NASDAQ and all prices are listed in US Dollars. Impel NeuroPharma employs 59 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Impel NeuroPharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMPL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Impel NeuroPharma stock price (NASDAQ: IMPL)

Use our graph to track the performance of IMPL stocks over time.

Impel NeuroPharma shares at a glance

Information last updated 2021-10-17.
Latest market close$9.94
52-week range$6.90 - $28.00
50-day moving average $14.06
200-day moving average $13.13
Wall St. target price$48.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-12.37

Buy Impel NeuroPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Impel NeuroPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Impel NeuroPharma price performance over time

Historical closes compared with the close of $9.94 from 2021-10-22

1 week (2021-10-15) 0.40%
1 month (2021-09-24) -23.71%
3 months (2021-07-23) -26.15%
6 months (2021-04-23) -33.73%
1 year (2020-10-21) N/A
2 years (2019-10-21) N/A
3 years (2018-10-21) N/A
5 years (2016-10-21) N/A

Impel NeuroPharma financials

Gross profit TTM $0
Return on assets TTM -104.31%
Return on equity TTM -333.3%
Profit margin 0%
Book value $2.64
Market capitalisation $193.1 million

TTM: trailing 12 months

Shorting Impel NeuroPharma shares

There are currently 940,118 Impel NeuroPharma shares held short by investors – that's known as Impel NeuroPharma's "short interest". This figure is 5.8% down from 997,995 last month.

There are a few different ways that this level of interest in shorting Impel NeuroPharma shares can be evaluated.

Impel NeuroPharma's "short interest ratio" (SIR)

Impel NeuroPharma's "short interest ratio" (SIR) is the quantity of Impel NeuroPharma shares currently shorted divided by the average quantity of Impel NeuroPharma shares traded daily (recently around 1.4 million). Impel NeuroPharma's SIR currently stands at 0.65. In other words for every 100,000 Impel NeuroPharma shares traded daily on the market, roughly 650 shares are currently held short.

To gain some more context, you can compare Impel NeuroPharma's short interest ratio against those of similar companies.

However Impel NeuroPharma's short interest can also be evaluated against the total number of Impel NeuroPharma shares, or, against the total number of tradable Impel NeuroPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Impel NeuroPharma's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Impel NeuroPharma shares in existence, roughly 50 shares are currently held short) or 0.1655% of the tradable shares (for every 100,000 tradable Impel NeuroPharma shares, roughly 166 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Impel NeuroPharma.

Find out more about how you can short Impel NeuroPharma stock.

Impel NeuroPharma share dividends

We're not expecting Impel NeuroPharma to pay a dividend over the next 12 months.

Impel NeuroPharma overview

Impel NeuroPharma, Inc. , a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington. .

Frequently asked questions

What percentage of Impel NeuroPharma is owned by insiders or institutions?
Currently 2.529% of Impel NeuroPharma shares are held by insiders and 76.802% by institutions.
How many people work for Impel NeuroPharma?
Latest data suggests 59 work at Impel NeuroPharma.
When does the fiscal year end for Impel NeuroPharma?
Impel NeuroPharma's fiscal year ends in December.
Where is Impel NeuroPharma based?
Impel NeuroPharma's address is: 201 Elliott Avenue West, Seattle, WA, United States, 98119
What is Impel NeuroPharma's ISIN number?
Impel NeuroPharma's international securities identification number is: US45258K1097

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site